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Broad Spectrum epidemiological
contribution of cannabis and other
substances to the teratological profile of
northern New South Wales: geospatial and
causal inference analysis
Albert Stuart Reece1,2,3* and Gary Kenneth Hulse1,2
Abstract
Background: Whilst cannabis commercialization is occurring rapidly guided by highly individualistic public
narratives, evidence that all congenital anomalies (CA) increase alongside cannabis use in Canada, a link with 21
CA’s in Hawaii, and rising CA’s in Colorado indicate that transgenerational effects can be significant and impact
public health. It was therefore important to study Northern New South Wales (NNSW) where cannabis use is high.
Methods: Design: Cohort. 2008–2015. Setting: NNSW and Queensland (QLD), Australia. Participants. Whole
populations. Exposures. Tobacco, alcohol, cannabis. Source: National Drug Strategy Household Surveys 2010, 2013.
Main Outcomes. CA Rates. NNSW-QLD comparisons. Geospatial and causal regression.
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Results: Cardiovascular, respiratory and gastrointestinal anomalies rose with falling tobacco and alcohol but rising
cannabis use rates across Queensland. Maternal age NNSW-QLD was not different (2008–2015: 4265/22084 v. 96,
473/490514 > 35 years/total, Chi.Sq. = 1.687, P = 0.194). A higher rate of NNSW cannabis-related than cannabis-
unrelated defects occurred (prevalence ratio (PR) = 2.13, 95%C.I. 1.80–2.52, P = 3.24 × 10− 19). CA’s rose more potently
with rising cannabis than with rising tobacco or alcohol use. Exomphalos and gastroschisis had the highest NNSW:
QLD PR (6.29(2.94–13.48) and 5.85(3.54–9.67)) and attributable fraction in the exposed (84.11%(65.95–92.58%) and
82.91%(71.75–89.66%), P = 2.83 × 10− 8 and P = 5.62 × 10− 15). In multivariable geospatial models cannabis was
significantly linked with cardiovascular (atrial septal defect, ventricular septal defect, tetralogy of Fallot, patent
ductus arteriosus), genetic (chromosomal defects, Downs syndrome), gastrointestinal (small intestinal atresia), body
wall (gastroschisis, diaphragmatic hernia) and other (hypospadias) (AVTPCDSGDH) CA’s. In linear modelling cannabis
use was significantly linked with anal stenosis, congenital hydrocephalus and Turner syndrome (ACT) and was
significantly linked in borderline significant models (model P < 0.1) with microtia, microphthalmia, and transposition
of the great vessels. At robust and mixed effects inverse probability weighted multivariable regression cannabis was
related to 18 defects. 16/17 E-Values in spatial models were > 1.25 ranging up to 5.2 × 1013 making uncontrolled
confounding unlikely.
Conclusions: These results suggest that population level CA’s react more strongly to small rises in cannabis use
than tobacco or alcohol; cardiovascular, chromosomal, body wall and gastrointestinal CA’s rise significantly with
small increases in cannabis use; that cannabis is a bivariate correlate of AVTPCDSGDH and ACT anomalies, is robust
to adjustment for other substances; and is causal.
Keywords: Cannabis, Teratology, Cardiovascular defects, Atrial septal defect, Gastroschisis, Exomphalos, Genotoxicity
Background
With major tobacco companies entering the cannabis
market it is clear that cannabis commercialization is well
under way [1]. Whilst much of the discussion relating to
cannabis use and cannabis control is notably self-
referential recent epidemiological reports suggest that in-
tergenerational effects may be both significant and power-
ful enough to impact population-level health outcomes.
A recent report on Canada demonstrated that total con-
genital defects were three times more common in the
northern Territories which smoked more cannabis than
the Provinces and that the association was robust to socio-
economic adjustment [2]. A recent study from Colorado
across the period of cannabis legalization showed that
many defects rose parallel to increased cannabis consump-
tion including all chromosomal defects (ACD), Downs
syndrome and several cardiovascular defects including
atrial septal defect (ASD) and patent ductus arteriosus
(PDA), common defects which had not been previously
linked with prenatal cannabis exposure (PCE) [3]. It was
calculated that in Colorado over 11,000 extra defects oc-
curred 2000–2014 related to increased cannabis use [3].
An Hawaiian study found that 21 defects were increased
in mothers who were exposed only to cannabis [4].
Whilst some of these studies have used sophisticated
geospatial modelling techniques [2] all epidemiological
research is fundamentally associational in nature. How-
ever similar findings elsewhere strengthens the evidence
base.
Northern New South Wales (NNSW, NSW) is a well
known drug using and cannabis cultivation area 760 km
from Sydney but only 180 km from tertiary pediatric
care centres in Brisbane and 111 km from Southport
both in Queensland (QLD). Although lying within New
South Wales administratively many of its neonatal CA’s
are evacuated to tertiary pediatric hospitals in Queens-
land under the Neonatal Retrieval Scheme (NRS) [5] and
their data thus appears in Queensland statistics. This
therefore presents an ideal opportunity to directly com-
pare NNSW and Queensland neonatal epidemiology.
Our hypothesis was that cannabis use would be associ-
ated with increased congenital anomalies and was for-
mulated prior to study commencement.
Methods
Data
Data on congenital anomaly rates for Queensland Health
service areas including northern New South Wales was
taken from the Congenital Anomaly Linked File (CALF)
from Queensland Health [6]. Annual data by area has
not been publicly released. Data on maternal age was
from the QLD and NSW annual Mothers and Babies re-
ports [7, 8]. CALF data includes numbers, rates and con-
fidence intervals for the data. Drug use data for last
month cigarette use, last month binge alcohol and last
year cannabis use by area was obtained from the Austra-
lian Institute of Health and Welfare from the National
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Drug Strategy Household Survey (NDSHS) 2010 and
2013 [9] and averaged to obtain a mean rate by area
across this period pursuant to our custom data request.
Data was matched manually between drug use and con-
genital anomaly datasets. Areal shapefiles were taken
from the Australian Government national website [10].
The northern coastal area of NSW was added on to the
Queensland Health shapefile. This depiction of the
NNSW catchment area is illustrative only and not
intended to be exact as the geographic boundaries of the
NRS are not defined [5].
Congenital anomalies were defined as cannabis re-
lated or not based on a literature review and recent
reports [2, 3, 11–13] particularly [4].
Sample characteristics
The samples were whole population samples and included
all births in all health regions of Queensland. Hence inclu-
sion and exclusion criteria were not applied as the samples
were complete population samples. Sample capture in
Northern New South Wales (NSW) appears to have been
incomplete as some birth defects were not captured in the
Queensland data and were managed in New South Wales.
Hence the Northern New South Wales rates described in
the present report clearly represents underestimates of the
total rates. As the NSW and Queensland datasets are not
directly comparable it is not possible to directly merge the
two datasets to form a complete picture. This study limita-
tion is discussed further in the limitations paragraph of
the Discussion.
Statistics
Data was processed in RStudio version 1.2.1335 based
on R version 3.6.1 on 16th April 2020. Two-by-two ta-
bles were analyzed in package epiR using epi.2by2.
Graphs were drawn with R-Base and ggplot2 [14] and in
Microsoft Excel. Maps were drawn using the R packages
ggplot2 and sf (“simple features”) [14, 15]. The software
is freely available online and is directly loaded from in-
side RStudio software downloaded from the Comprehen-
sive “R” Archive Network (CRAN). Licences for all R
software are freely available with the R packages sourced
from CRAN and its various mirrors internationally. Prin-
cipal component analysis was conducted using the psych
package. Linear regression was performed in Base-R.
Batch extraction of all linear model coefficients by differ-
ent defects was performed with broom and purrr pack-
ages. Correction of P-values for multiple testing was
applied using the corrections of Holm, Bonferroni, Ben-
jamini and Yekutieli, False Discovery Rate and Hommel
as indicated. Links between neighbouring areas sharing
an edge or corner (“queen”-relationships by analogy with
chess moves) were derived with the poly2nb function
from spdep and edited as indicated. This neighbourhood
map was used to calculate the geospatial weights matrix
for spatial regression.
Geospatial regression was performed with the spreml func-
tion from package splm [13, 16] using the derived spatial
weights matrix. Spatial models may include the parameters
phi, psi, rho and lambda for random effects in the error term,
serial autocorrelation in the residuals, spatial errors, and
autocorrelation in the spatial errors respectively. All spatial
models used a full error structure of Kapoor Kelejian and
Prucha [17] and had serially correlated remainder errors and
random effects (sem2srre). The appropriateness of this error
structure was formally tested by substituting various alterna-
tive forms and comparing results including the maximum
likelihood ratio at model optimization (LogLik in the tables)
and spatial Hausman tests and by examining the significance
of the final model parameters [18]. Models were spatially
lagged and not lagged as indicated.
Inverse probability weights (IPW) were derived with the
ipw package in R using cannabis use as the exposure of
interest, tobacco in the numerator and tobacco and alco-
hol in the denominator. IPW weights were then used in
robust regression models conducted in the R package sur-
vey, and in mixed effects models in the R package nlme to
generate datasets pseudo-randomized for cannabis expos-
ure. This allowed causal relationships to be assessed. E-
Values were calculated with the R package EValue to
quantify the degree of association some unmeasured con-
founder would require with both dependent and inde-
pendent variables to explain away the observed effect.
It was necessary to use various regression model struc-
tures for several reasons. Only spatial models can capture
the spatial effects amongst the data, however they cannot
be inverse probability weighted, so that causality can not
be studied directly from them. Spatial models do provide
a model variance which allows e-Values to be calculated
from them. Robust marginal structural models can be in-
verse probability weighted, but do not provide model
standard deviations so that e-Values cannot be calculated
from them directly. Mixed effects models can be inverse
probability weighted and also provide model standard de-
viations, but do not capture spatial effects and are also not
robust in design. Hence for a full picture and understand-
ing of the causal and spatial processes involved one needs
to consider output from all of these various model struc-
tures together with their applicable e-Values.
For all regression models model reduction was by the
classical method with sequential deletion of the least sig-
nificant term. Missing data was casewise deleted at mul-
tivariable regression. P < 0.05 was considered significant.
Data availability statement
Data including R software code have been made avail-
able online in the Mendeley Data Repository at https://
doi.org/10.17632/cjzfyktz5m.1.
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Table 1 Results of geospatial additive regression by selected congenital anomalies - spatial error models
Parameters Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
INTERACTIVE MODELS
spreml(Atrial_Septal_Defects ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Binge_Alcohol: Cannabis −0.58 (− 1.12, − 0.04) 0.0376 phi 0.0101 NA
Tobacco: Binge_Alcohol: Cannabis 0.03 (0, 0.06) 0.0417 psi 9.1E-08 1.0000
Tobacco: Cannabis −0.09 (−0.18, 0) 0.0423 rho −0.9960 0.0037
CHROMOSOMAL_Defects
Tobacco: Binge_Alcohol: Cannabis −0.01 (− 0.01, − 0.01) 0.0007 phi 0.0890 NA
Binge_Alcohol: Cannabis 0.05 (0.02, 0.08) 0.0021 psi 2.2E-05 0.9999
Tobacco: Cannabis 0.02 (0.01, 0.03) 0.0047 rho −0.9805 0.0058
Tobacco: Binge_Alcohol 0.02 (0, 0.04) 0.0184
Diaphragmatic_Hernia
Cannabis 7.26 (3.21, 11.31) 0.0004 phi 0.0095 0.9964
Binge_Alcohol 7.33 (3.15, 11.51) 0.0006 psi −1.7E-07 1.0000
Binge_Alcohol: Cannabis −2.07 (−3.26, − 0.88) 0.0006 rho 0.9660 <2e-16
Tobacco: Cannabis −0.22 (− 0.37, − 0.07) 0.0041
Tobacco: Binge_Alcohol: Cannabis 0.06 (0.02, 0.1) 0.0051
Tobacco 0.17 (0.04, 0.3) 0.0091
Downs Syndrome
Binge_Alcohol: Cannabis 0.03 (0.02, 0.04) 3.4E-05 phi 0.0571 NA
Binge_Alcohol −2.33 (−3.7, − 0.96) 0.0008 psi 3.6E-05 0.9998
rho −0.6662 0.0626
Gastroschisis




Tobacco: Cannabis −0.13 (− 0.22, − 0.04) 0.0062 phi 0.0027 NA
Tobacco: Binge_Alcohol: Cannabis 0.04 (0.01, 0.07) 0.0084 psi 4.3E-05 0.9999
Tobacco: Binge_Alcohol −0.35 (− 0.66, − 0.04) 0.0266 rho −0.2080 0.6705
Tobacco 1.13 (0.11, 2.15) 0.0304
Patent_Ductus_Arteriosus
Cannabis 0.24 (0.01, 0.47) 0.0358 phi 0.0109 NA
Binge_Alcohol: Cannabis −0.06 (−0.12, 0) 0.0526 psi 1.8E-06 1.0000
rho −0.9998 0.0022
Small Intestinal Stenosis / Atresia




Cannabis 0.09 (0.04, 0.14) 0.0007 phi 0.1102 0.9963
psi 5.7E-05 0.9998
rho 0.3074 0.3382
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Ethics
This study was approved by the Human Research Ethics
Committee of the University of Western Australia on
15th April 2020 (No. RA/4/20/4724).
Results
Input data is shown in an online supplementary csv file.
Supplementary Table 1 provides comparative congenital
anomaly data between QLD and NSW by both numbers
and rates including defect relationship to cannabis [6]. De-
nominator data was calculated from the numbers and
rates supplied in that file. It was verified from the annual
QLD Health Mothers and Babies reports 2008–2015
which show 509,095 births in this period [8]. The “Inter-
state and Overseas” designation in the CALF file includes
offshore islands such as Christmas, Norfolk, Cocos and
Lord Howe Islands which together have a population of
4518. The prime catchment area of the NRS is Northern
NSW which has a population of 296,531 [10]. Hence only
1.5% of the population in this designation is likely to come
from outside NNSW. The view that the “Interstate and
Overseas” designation refers primarily to NNSW is
Table 1 Results of geospatial additive regression by selected congenital anomalies - spatial error models (Continued)
Parameters Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
Ventricular_Septal_Defect
Tobacco: Cannabis −0.11 (− 0.21, − 0.01) 0.0328 phi 0.4947 NA
Tobacco: Binge_Alcohol: Cannabis 0.03 (0, 0.06) 0.0372 psi 1.2E-04 0.9997
Cannabis 2.93 (−0.23, 6.09) 0.0692 rho −1.0000 0.0306
Binge_Alcohol: Cannabis −0.85 (−1.79, 0.09) 0.0750
Fig. 1 Trend analysis over time of (a) drugs and (b) various congenital defects and defect classes
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Fig. 2 Choropleth maps of congenital anomaly class rates across QLD and NNSW. High rates are shown in yellow and low rates in dark blue.
Maps were drawn using R package “sf” [15]
Fig. 3 Choropleth maps of various chromosomal anomaly rates across QLD and NNSW. High rates are shown in yellow and low rates in dark
blue. Maps were drawn using R package “sf” [15]
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confirmed by QLD Health Ministerial correspondence
(Minister Steven Miles, 05/04/2018). The denominator
figure calculated for NNSW in this manner is 4800 births.
It should be noted that NNSW birth defect data also
appears in NSW Health records [7]. One notes that the
rates of congenital anomalies reported for this region in
the NSW Mothers and Babies reports are about half
those of the rest of the state. This is presumably related
to the relocation of many cases into Queensland through
the NRS. Queensland congenital anomaly rates are much
higher than those reported elsewhere so it is not possible
simply to combine NSW and QLD Health reports.
Therefore this report is limited to consideration of the
QLD Health CALF file only.
Fig. 4 Confidence Intervals of cannabis-related and cannabis-unrelated congenital anomalies for (a) common, (b) intermediate frequency and (c)
rare congenital anomalies
Fig. 5 Confidence Intervals of rare cannabis-related and cannabis-unrelated congenital anomalies in more detail
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Fig. 6 Relative Rates of Congenital Anomalies in Queensland v NNSW
Fig. 7 Relative Rate Ratios between Queensland and NNSW by relationship to Cannabis
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Drug use data is shown in Supplementary Table 2. It
is noteworthy that the Richmond-Tweed NNSW area
has a middle ranking for tobacco and alcohol use, but a
first ranking for cannabis use.
Maternal age is a major factor bearing on congenital
anomaly rates and it is known to be strongly linked with
chromosomal anomaly rates. For years 2008–2015 4265/
22084 (19.31%) births in NNSW were to mothers > 35
years compared to 96,493/490514 (19.67%; 18,581 miss-
ing maternal age data) in Queensland (Chi.Sq. = 1.687,
df = 1, P = 0.194). This compares to 22,133/92242
(23.9%) of 2012 births in the rest of NSW (Chi.Sq. =
98.954, df = 1, P = 4.33 × 10− 10) indicating that NNSW
mothers are younger in than elsewhere in NSW.
Interestingly CALF Table 1 shows rises in the rates of
several defects (Fig. 1) including CVS defects, atrial sep-
tal defect (ASD) and ventricular septal defect (VSD)
which are highly significant (Supplementary Table 3). In-
triguingly the mean incidence of daily smoking tobacco
and high risk alcohol use dropped across this period and
annual cannabis use rose from 10.5 to 11.3%. The princi-
pal component of the combination of cardiovascular,
Fig. 8 Log (Relative Rate Ratios) between Queensland and NNSW by relationship to Cannabis
Fig. 9 Prevalence Ratios (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
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gastrointestinal and respiratory anomalies also rose sig-
nificantly across this period. These data suggest that
cannabis may be a more potent and more important ter-
atogen than tobacco and alcohol.
Figure 2 shows a qualitative choropleth map-graph for
the major CA classes. The yellow zones reflect high inci-
dence and dark blue low incidence.
Supplementary Figs. 1–3 present choropleth maps of
CA incidence by area. Figure 3 shows chromosomal
anomaly incidence for which data is available.
Figure 4 was drawn in Excel and shows the confidence
intervals from CALF for common, intermediate frequency
and rare defects for cannabis-related (CRD) and cannabis
not related (CNRD) defects. For most of the cannabis-
unrelated defects the confidence intervals overlap. For
most of the cannabis-related defects the confidence inter-
vals either do not overlap, or are near the lower end of the
QLD C.I.’s. Figure 5 expands this list for rare congenital
anomalies and in general terms tends to continue this
trend of non-overlapping confidence intervals or
Fig. 10 Attributable Fraction in the Exposed for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
Fig. 11 Attributable Fraction in the Population for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
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Fig. 12 P-Values for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
Fig. 13 Response of five major congenital anomaly classes to (a) Tobacco, (b) Alcohol and (c) cannabis exposure
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confidence intervals at the more extreme end of the range
of the confidence intervals for cannabis-related defects.
Figure 6 compares the QLD and NNSW CA rates
based on the relative rates quoted in the Queensland
CALF file.
Figure 7 compares all the rate ratios of defects using the
quoted rates in the CALF file. Figure 8 makes a similar
comparison with log rates and shows clearly that most of
the cannabis-related defects are more common in NNSW.
CNRD were more common in QLD (23,737/509095,
4.66% v 185/4800, 3.85%, Chi Sq. = 7.002, df = 1, P =
0.0081). CRD were more common in NNSW (394/4800
8.21% v 16,346/509095, Chi Squ. = 376.86, df = 1, P =
6.01 × 10− 84). CRD were more common in NNSW than
CNRD (394/4800 v 185/4800, Prevalence Ratio (PR) = 2.13
(95%C.I. 1.80–2.52), Chi Sq. = 80.284, P = 3.24 × 10− 19).
Supplementary Table 4 lists the PR’s, attributable frac-
tion in the exposed (AFE) and attributable fraction in
the population (AFP) along with their C.I.’s and applic-
able P-values for all defects and defect classes. They de-
cline from exomphalos (PR = 6.29 (2.94–13.48), AFE =
84.11% (65.95–92.58%) and AFP = 4.71% (0.55–8.69%))
and gastroschisis (PR = 5.85 (3.54–9.67), AFE = 82.91%
(71.75–89.66%) and AFP = 4.34% (1.79–6.82%)).
Figure 9 illustrates the PR’s and C.I.’s for CRD and
CNRD. Figure 10 shows the AFE’s and C.I.’s for CRD
and CNRD. Figure 11 shows the AFP’s and C.I.’s for
CRD and CNRD. P-values are illustrated in Fig. 12.
Figure 13 shows five main defect classes charted
against the use of tobacco, binge alcohol and cannabis.
Rising trends with cannabis seem to apply to CNS, car-
diovascular and chromosomal anomalies.
Figure 14 charts all 55 anomalies and anomaly classes
against tobacco use. Figure 15 performs a similar func-
tion for binge alcohol.
When a similar exercise is undertaken for cannabis
exposure rising trends appear in several defects in
the top three rows especially in cardiovasculature,
chromosomal anomalies and body wall defects
(Fig. 16).
Supplementary Table 5 lists the regression coefficients
and their significance levels in ascending order of P-values
for cannabis exposure. Supplementary Tables 6 and 7
show this table listed in order of ascending P-values for
tobacco and alcohol respectively.
Supplementary Table 8 lists the significant output of a
linear regression where the defect rate was related to
additive terms of tobacco, binge alcohol use and
Fig. 14 Congenital Anomaly Rate by Cannabis Use Rate – Ordered by Slopes of Least Squares Regression Lines
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cannabis use and includes all P < 0.3. This procedure se-
lects 18 defects for further study. For biological and epi-
demiological reasons Trisomies 13 and 18 were also
included.
Spatial analysis algorithms do not tolerate missing
data. Hence linear regression was used to investigate 8
defects where spatial data was incomplete. Supplemen-
tary Table 8 shows the results of a model interactive in
substances. Cannabis use was identified as being linked
with several defects in this table including Turners
syndrome.
Figure 17 shows the geospatial relationships which
were derived from spdep::poly2nb and then edited to in-
clude all geospatial links.
Table 1 gives the results of geospatial regression for a
model with additive terms in drug exposure. These are
spatial error models and are not spatially lagged. In the
additive model series cannabis is independently linked
with all eight anomalies particularly cardiovascular
(ASD, PDA and tetralogy of Fallot, ToF) and chromo-
somal (ACD and Downs syndrome), gastroschisis and
small intestinal atresia.
Table 2 shows the results of an interactive spatial
model and finds that cannabis is more strongly linked
with these same defects. VSD is now positively associ-
ated as is diaphragmatic hernia which have both been
previously noted to be cannabis-associated [19, 20].
A similar exercise is executed for spatially lagged
spatial error (spatially autocorrelated with autocorrelated
error components, SARAR) additive (Table 3) and inter-
active (Table 4) models with very similar results. In each
case spatial error models were superior to combined
SARAR models, as judged by the log maximum likeli-
hood values, spatial Hausman tests and the largely non-
significant lambda coefficients.
One notes also that in a number of spatial error
models spatial model parameters rho and lambda are
noted to be highly significant. This therefore justifies the
use of spatial models and also suggests that spatial fac-
tors are significant in considering clinical teratological
patterns.
Table 5 summarizes the results of the above spatial
models to facilitate comparisons between the various
substances. The four spatial model structures are listed
across the top of the Table and the various substances
are listed in the rows. One notes that cannabis was inde-
pendently predictive in 27 of the 36 models compared to
only five each for tobacco and alcohol. Cannabis was
Fig. 15 Congenital Anomaly Rate by Tobacco Use Rate – Ordered by Slopes of Least Squares Regression Lines
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Fig. 16 Congenital Anomaly Rate by Alcohol Use Rate – Ordered by Slopes of Least Squares Regression Lines
Fig. 17 Geospatial Links Between regions – (a) Edited and (b) Final. Maps were drawn using R package “sf” [15]
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Table 2 Results of geospatial interactive regression by selected congenital anomalies spatial error models
Parameters Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
ADDITIVE MODELS
spreml(log(Atrial_Septal_Defects) ~ DlyCigs11 + log(RiskAlc11) + Cannabis)
Atrial Septal Defect








Cannabis 0.09 (0.05, 0.13) 2.9E-05 phi 5.57E-02 NA
Binge_Alcohol −2.02 (−3.35, − 0.69) 0.0029 psi 3.57E-05 0.9999
rho −6.85E-01 0.0883
Gastroschisis








Cannabis 0.03 (0.01, 0.05) 0.0453 phi 1.01E-02 NA
psi −9.20E-06 1.0000
rho −1.0E+ 00 0.0025
Small Intestinal Stenosis / Atresia








spreml(Atrial_Septal_Defects ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Binge_Alcohol: Cannabis −0.58 (−1.12, − 0.04) 0.0376 phi 0.0101 NA
Tobacco: Binge_Alcohol: Cannabis 0.03 (0, 0.06) 0.0417 psi 9.1E-08 1.0000
Tobacco: Cannabis −0.09 (− 0.18, 0) 0.0423 rho −0.9960 0.0037
CHROMOSOMAL_Defects
Tobacco: Binge_Alcohol: Cannabis −0.01 (− 0.01, − 0.01) 0.0007 phi 0.0890 NA
Binge_Alcohol: Cannabis 0.05 (0.02, 0.08) 0.0021 psi 2.2E-05 0.9999
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Table 2 Results of geospatial interactive regression by selected congenital anomalies spatial error models (Continued)
Parameters Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
Tobacco: Cannabis 0.02 (0.01, 0.03) 0.0047 rho −0.9805 0.0058
Tobacco: Binge_Alcohol 0.02 (0, 0.04) 0.0184
Diaphragmatic_Hernia
Cannabis 7.26 (3.21, 11.31) 0.0004 phi 0.0095 0.9964
Binge_Alcohol 7.33 (3.15, 11.51) 0.0006 psi −1.7E-07 1.0000
Binge_Alcohol: Cannabis −2.07 (−3.26, − 0.88) 0.0006 rho 0.9660 <2e-16
Tobacco: Cannabis −0.22 (− 0.37, − 0.07) 0.0041
Tobacco: Binge_Alcohol: Cannabis 0.06 (0.02, 0.1) 0.0051
Tobacco 0.17 (0.04, 0.3) 0.0091
Downs Syndrome
Binge_Alcohol: Cannabis 0.03 (0.02, 0.04) 3.4E-05 phi 0.0571 NA
Binge_Alcohol −2.33 (−3.7, −0.96) 0.0008 psi 3.6E-05 0.9998
rho −0.6662 0.0626
Gastroschisis




Tobacco: Cannabis −0.13 (− 0.22, − 0.04) 0.0062 phi 0.0027 NA
Tobacco: Binge_Alcohol: Cannabis 0.04 (0.01, 0.07) 0.0084 psi 4.3E-05 0.9999
Tobacco: Binge_Alcohol −0.35 (− 0.66, − 0.04) 0.0266 rho −0.2080 0.6705
Tobacco 1.13 (0.11, 2.15) 0.0304
Patent_Ductus_Arteriosus
Cannabis 0.24 (0.01, 0.47) 0.0358 phi 0.0109 NA
Binge_Alcohol: Cannabis −0.06 (−0.12, 0) 0.0526 psi 1.8E-06 1.0000
rho −0.9998 0.0022
Small Intestinal Stenosis / Atresia








Tobacco: Cannabis −0.11 (− 0.21, − 0.01) 0.0328 phi 0.4947 NA
Tobacco: Binge_Alcohol: Cannabis 0.03 (0, 0.06) 0.0372 psi 1.2E-04 0.9997
Cannabis 2.93 (− 0.23, 6.09) 0.0692 rho −1.0000 0.0306
Binge_Alcohol: Cannabis −0.85 (−1.79, 0.09) 0.0750
Technical Abbreviations: phi Idiosyncratic component of the spatial error termpsi: individual time-invariant component of the spatial error termrho: spatial
autoregressive parameter, lambda: spatial autocorrelation coefficient
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Table 3 Results of geospatial additive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models
Parameter Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
Atrial Septal Defect





Cannabis 0.04 (0.01, 0.07) 0.0227 phi 0.0072 0.9998









Cannabis 0.09 (0.05, 0.14) 2.7E-05 phi 0.0135 NA
























Tobacco −0.03 (− 0.05, 0) 0.0166 phi 0.0068 0.9995
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involved in 19 interactive terms compared to ten and 13
for alcohol and tobacco respectively. It follows therefore
that cannabis was involved in 46 terms compared to 15
and 18 for alcohol and tobacco respectively.
Having demonstrated a strong associational relation-
ship between drug exposure and several congenital
anomalies the next issue of importance relates to the
issue of whether the relationship was causal or not. In-
verse probability weights were generated and used to de-
rive a dataset pseudorandomized for cannabis exposure.
Data was processed by robust interactive generalized lin-
ear modelling functions. As shown in Table 6 cannabis
was significantly related to 18 anomalies either alone or
in interaction with tobacco and alcohol.
This exercise was repeated with (non-robust) mixed
effects modelling as such models in R have standard de-
viations associated with them, which is required in the
E-values algorithm which follows. As shown in Table 7
similar results were obtained for 11 congenital
anomalies.
It is conceivable that the described relationships were
related to some factor other than the measured covari-
ates. E-Values quantitate the degree of association re-
quired of some unmeasured confounder with both
cannabis exposure and the dependent variables to ex-
plain away the described effect. One notes that 1.25 is
the value quoted in the literature as the threshold of
interest in sensitivity analyses [21]. Table 8 lists 27 e-
Values and finds that 21 minimum e-Values were
greater than 1.25 and ranged up to 3.8 × 1030 for geospa-
tial models and up to infinity for mixed effects models,
making uncontrolled confounding unlikely.
Discussion
This investigation presents many intriguing findings.
Despite the several technical shortcomings of this data-
set it is fascinating for the details and tantalizing clues
which have been revealed. Importantly most of its major
findings have been confirmed previously in other loca-
tions particularly in Colorado, Hawaii, Canada, and USA
and by professional bodies such as AHA, AAP and CDC
lending support to the strength of its principal results [2,
3, 11, 13, 19, 20].
NNSW has higher prevalence rates of the cannabis
related anomalies: neural tube defects; small intestinal
atresia; body wall defects: exomphalos, gastroschisis,
diaphragmatic hernia; the cardiovascular disorders:
ASD, VSD, PDA, tetralogy of Fallot, and transposition
of the great vessels (TxGrVess); and the genetic disor-
ders: all chromosomal disorders, Downs syndrome,
Turners syndrome and trisomy 18. Amongst the de-
fect classes cardiovascular, respiratory, and chromo-
somal anomalies were elevated. Some of these
associations have been previously reported [3, 4, 22]
and were seen in our unpublished analyses of US
data.
QLD Health data showed that the NNSW CI’s for
CRD’s were mostly non-overlapping or were at the ex-
treme end of the QLD CI’s. CRD’s had higher rate ratios
than CNRD’s.
Rising rates of cardiovascular, gastrointestinal and re-
spiratory defects, and their first principal component
were associated with falling rates of tobacco and alcohol
use but rising cannabis use, just as was found in Color-
ado and USA [3].
At geospatial and linear regression the cardiovascular
defects ASD, VSD, PDA, ToF, TxGrVess; the chromo-
somal defects ACD, Downs, Turners, Trisomy 13; the
body wall defects gastroschisis, exomphalos, diaphrag-
matic hernia; the GI disorders small intestinal atresia
and anal stenosis were all linked with cannabis exposure
and for most cannabis exposure was an independent risk
factor.
Rising rates of cannabis exposure were more strongly
associated with cardiovascular, chromosomal, gastro-
intestinal and body wall defects than were rising rates of
tobacco or alcohol exposure.
Analysis of this dataset by the formal techniques of
causal inference analysis including inverse probability
weighting and E-Values demonstrated that the described
relationships fulfil the criteria for causal relationships.
These results show a striking concordance with epi-
demiological series from elsewhere. ASD, VSD, ToF, ob-
structive urinary disorders, hydrocephalus, anal
anomalies and Downs syndrome were linked with PCE
in a large Hawaiian series [4]. VSD has previously been
linked with PCE [19]. Neural tube defects were noted to
be elevated in a cannabis-related manner in Canada and
Hawaii [4, 11]. ASD, PDA ACD and Downs were seen to
rise in close temporal association with increased
Table 3 Results of geospatial additive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models (Continued)
Parameter Model
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Table 4 Results of geospatial interactive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models
Parameter Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
Atrial_Septal_Defect





Tobacco: Cannabis 0.01 (0, 0.02) 0.0142 phi 0.0380 0.9971









Binge_Alcohol: Cannabis 0.03 (0.01, 0.04) 3.1E-05 phi 0.0158 NA









Tobacco: Cannabis −0.12 (− 0.2, − 0.04) 0.0035 phi 0.2455 NA
Tobacco: Binge_Alcohol: Cannabis 0.03 (0.01, 0.06) 0.0050 psi −0.0002 0.9994
Tobacco: Binge_Alcohol −0.33 (− 0.61, − 0.06) 0.0184 rho 0.0263 0.9544
Tobacco 1.09 (0.17, 2.01) 0.0201 lambda −0.4710 0.1431
Patent_Ductus_Arteriosus
Cannabis 0.26 (0.04, 0.49) 0.0208 phi 0.0100 0.9992









Cannabis 0.05 (0, 0.1) 0.0370 phi 0.0105 0.9993
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cannabis use in Colorado [3]. Exomphalos was impli-
cated in animals [23, 24] and in some clinical series in-
cluding in Queensland [25]. Transposition of the great
vessels has previously been linked with paternal PCE
[26]. Indeed in Canada total CA’s were linked with in-
creased cannabis use after controlling for income and
sociodemographic variables [2].
Many series implicate PCE in gastroschisis aetiology
with a meta-analyzed bivariate O.R. = 4.12 (95%C.I.
3.45–4.91) [4, 27–32]. Our findings PR = 5.85 (3.54–
9.67) contradict those of a 2011 NSW Health report on
gastroschisis in this region [33] which erroneously ap-
plied an inflated Bonferroni correction to obviate a sig-
nificant result. Indeed if the 9 cases reported in NSW
[33] are added to the 16 cases reported in QLD the PR
rises further to 9.13 (6.07–13.72).
Increasing reports from diverse sources indicate that
the evidence is building that cannabis has significant
teratological activities in humans in agreement with ani-
mal studies where many severe defects including oedema,
exomphalos, phocomelia, spina bifida, myelocoele, exence-
phaly and foetal loss were documented [23, 24]. Concord-
ant reports from Hawaii, Colorado and Canada suggest
that the findings reported herein are indeed valid and are
generalizable elsewhere. Given that likely half the NNSW
congenital anomalies are reported internally within NSW
[7] this suggests that the teratological situation in NNSW
is indeed serious. Moreover some of the CA described
here, especially chromosomal defects, are heavily thera-
peutically aborted antenatally again suggesting that the
situation may well be much worse than our description
suggests. Our analysis strongly implicates cannabis use as
a likely underlying factor.
When one also considers the known epigenetic actions
of cannabis [2, 12, 34–37] and its associations with devel-
opmental neurological dysfunction and autism [38–42]
concerns relating to the intergenerational actions of can-
nabis are heightened.
From both the present data and from similar inter-
national analyses a number of important clinical implica-
tions arise. Notwithstanding its popular relatively benign
image such analyses indicated not only that the potential
teratological impacts of cannabis are significant but that
they are likely causal in nature. Patients considering
commencing a family should be encouraged to desist
from all drugs prior to conception including cannabis.
Patients who do fall pregnant and who are consuming
cannabis should be encouraged to reduce and cease. Pa-
tients wishing to access treatment to assist with such
withdrawal should be provided every encouragement
and assistance to do so. Patients should be warned that
the evidence base for the use of cannabis for most of its
touted clinical indications is weak. Patients should be
advised to avoid cannabis for morning sickness of
Table 4 Results of geospatial interactive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models (Continued)
Parameter Model
Parameter Estimate (C.I.) P-Value Parameters Value P-Value
Tobacco: Cannabis 0 (0, 0) 0.0420 psi 4.3E-06 1.0000
rho −0.9997 0.0360
lambda −0.2285 0.6320











Number of Models 8 10 9 9 36
Cannabis
Independently
8 5 8 6 27
Alcohol
Independently
1 2 1 1 5
Tobacco
Independently
0 2 2 1 5
Cannabis Interactively 0 12 0 7 19
Alcohol Interactively 0 6 0 4 10
Tobacco Interactively 0 8 0 5 13
Total Cannabis 8 17 8 13 46
Total Alcohol 1 8 1 5 15
Total Tobacco 0 10 2 6 18
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Table 6 Robust generalized linear regression models
Parameter Estimate (95%C.I.) P-Value
PC1
Cannabis 3.46 (0.58, 6.34) 0.0382
Cigarettes: Alcohol 0.45 (0.04, 0.85) 0.0521
Cigarettes −1.52 (−2.89, − 0.16) 0.0510
Alcohol: Cannabis −1 (−1.82, − 0.17) 0.0369
PC1 as Arcsinh
Cannabis 2.89 (0.87, 4.92) 0.0172
Cigarettes: Alcohol 0.39 (0.11, 0.67) 0.0212
Cigarettes −1.31 (−2.26, − 0.36) 0.0204
Alcohol: Cannabis −0.85 (− 1.43, − 0.26) 0.0162
Central Nervous System
Anencephalus
Cigarettes: Cannabis 0.1 (0.04, 0.16) 0.0065
Cigarettes: Alcohol 0.55 (0.1, 1) 0.0384
Cigarettes −1.81 (−3.32, − 0.31) 0.0399
Cigarettes: Alcohol: Cannabis −0.03 (− 0.05, − 0.01) 0.0068
CNO
Alcohol 2.8 (0.84, 4.76) 0.0189
Cannabis 2.6 (1.06, 4.14) 0.0078
Cigarettes: Alcohol: Cannabis 0.02 (0.01, 0.04) 0.0156
Cigarettes: Cannabis −0.08 (− 0.14, − 0.02) 0.0194
Alcohol: Cannabis − 0.79 (−1.25, − 0.34) 0.0067
Cardiovascular System
ASD
Cigarettes: Alcohol: Cannabis 0.12 (0.06, 0.18) 0.0051
Cannabis 8.4 (3.93, 12.88) 0.0062
Alcohol 21.3 (8.16, 34.43) 0.0130
Cigarettes 3.48 (1.07, 5.89) 0.0223
Cigarettes: Alcohol −1.05 (− 1.78, −0.32) 0.0227
Alcohol: Cannabis −2.5 (−3.8, −1.19) 0.0056
Cigarettes: Cannabis −0.4 (− 0.61, − 0.19) 0.0055
VSD
Cigarettes: Alcohol: Cannabis 0.04 (0.01, 0.07) 0.0242
Cannabis 3.38 (0.63, 6.13) 0.0366
Alcohol: Cannabis −0.98 (−1.79, − 0.18) 0.0381
Cigarettes: Cannabis −0.13 (− 0.23, − 0.03) 0.0239
PDA
Cannabis 6.68 (1.28, 12.07) 0.0416
Cigarettes: Alcohol: Cannabis 0.09 (0.01, 0.16) 0.0504
Alcohol 16.71 (0.91, 32.5) 0.0719
Cigarettes: Cannabis −0.29 (− 0.53, − 0.04) 0.0536
Alcohol: Cannabis −1.98 (−3.55, − 0.4) 0.0392
Tetralogy Fallot
Cannabis 0.08 (0.01, 0.15) 0.0410
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Table 6 Robust generalized linear regression models (Continued)
Parameter Estimate (95%C.I.) P-Value
Gastrointestinal System
Cigarettes: Alcohol: Cannabis 0.02 (0.01, 0.03) 0.0031
Cigarettes 0.7 (0.27, 1.13) 0.0090
Cigarettes: Alcohol −0.22 (−0.35, − 0.09) 0.0081
Cigarettes: Cannabis −0.07 (− 0.11, − 0.04) 0.0029
Small Intestinal Stenosis or Atresia - Additive
Cannabis 0.043 (0.004, 0.081) 0.0463
Small Intestinal Stenosis or Atresia - IR
Cigarettes: Cannabis 0.002 (0, 0.005) 0.0692
Genitourinary System
Cigarettes: Alcohol: Cannabis 0.01 (0, 0.01) 0.0113
Cigarettes 0.28 (0.08, 0.48) 0.0199
Cigarettes: Alcohol −0.09 (− 0.15, − 0.02) 0.0195
Cigarettes: Cannabis − 0.03 (− 0.04, − 0.01) 0.0103
Renal Pelvis Obstruction
Alcohol: Cannabis 0.65 (0.1, 1.21) 0.0425
Cigarettes: Cannabis 0.08 (0, 0.15) 0.0656
Cigarettes: Alcohol: Cannabis −0.02 (− 0.04, 0) 0.0614
Cannabis −2.17 (−4.03, − 0.31) 0.0450
Chromosomal Anomalies
Alcohol: Cannabis 0.02 (0, 0.05) 0.0678
Alcohol −0.82 (−1.62, − 0.02) 0.0684
GIT
Cigarettes: Cannabis 0.04 (0.01, 0.08) 0.0380
Cigarettes: Alcohol 0.34 (−0.01, 0.68) 0.0878
Cigarettes −1.07 (−2.17, 0.02) 0.0862
Cigarettes: Alcohol: Cannabis −0.01 (− 0.03, 0) 0.0357
Respiratory
Cigarettes: Cannabis 0.01 (0, 0.02) 0.0927
Cigarettes: Alcohol: Cannabis 0 (−0.01, 0) 0.0497
Downs - Additive
Cannabis 0.04 (0.01, 0.07) 0.0186
Alcohol −1.29 (−2.43, − 0.15) 0.0464
Downs - Interactive
Cigarettes 0.21 (0.01, 0.41) 0.0599
Cigarettes: Alcohol −0.07 (− 0.13, − 0.01) 0.0441
Cigarettes: Alcohol: Cannabis 0.0007 (0.0002, 0.0013) 0.0198
Body Wall
Musculoskeletal
Cannabis 2.71 (0.93, 4.49) 0.0123
Cigarettes: Cannabis −0.13 (− 0.22, − 0.05) 0.0113
Alcohol: Cannabis − 0.8 (−1.32, − 0.27) 0.0130
Cigarettes: Alcohol: Cannabis 0.04 (0.01, 0.06) 0.0118
Gastroschisis
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pregnancy. Heavy cannabis smokers should be warned
that cannabis hyperemesis can mimic hyperemesis
gravidarum.
Moreover since the debate relating to cannabis is typ-
ically highly individualistic it seems prudent that medical
professional organizations should partner with public
health agencies and community groups to enlarge the
focus of popular debate from the simply self-referential
to a broader multigenerational perspective.
One major toxicological conclusion which follows dir-
ectly from these studies is that access to cannabis should
be highly restricted. Indeed such work calls into ques-
tion the whole issue of the long term advisability of can-
nabis medicalization / legalization and the sustainability
of such paradigms from a teratological perspective.
The present work has not considered neurological sequa-
lae in the newborn and childhood as has previously been re-
ported to overlap the autistic spectrum disorder and ADHD
and thereby potentially play a major role in the modern
widespread epidemic of these disorders [38–40, 43]. When
such data is factored into consideration the imperatives for
reconsideration and re-evaluation of cannabis legalization
overall are largely increased.
Comparison with alcohol
It is of interest to summarize and compare some of these re-
sults directly between cannabis and alcohol as the latter is a
known human foetal teratogen and many learned bodies rec-
ommend strongly against tobacco exposure in pregnancy [44].
Figure 13 is a scatterplot of the frequency of the defect
classes compared to the various substances. This Figure
shows clearly that increasing cannabis use is associated
much more strongly with several classes of congenital
anomalies in this dataset than either tobacco or alcohol.
The regression lines in this figure slope upwards much
more strongly for cannabis for CNS defects, cardiovascu-
lar defects and chromosomal defects than for either of
the other two substances.
Figures 14, 15 and 16 perform a similar role for each
individual defect by the three substances tobacco, alco-
hol and cannabis. On the tobacco and alcohol scatter-
plots most of the regression lines are flat or falling. In
contradistinction on the cannabis scatterplot many of
the first 32 defects appear to be rising with positive
slope. This is quantified in Supplementary Tables 5–7
for cannabis, tobacco and alcohol respectively. The
slopes of the first 8 CA’s are significant and seven slopes
are positive for cannabis. This compared to tobacco and
alcohol where only two and four slopes are significant
respectively and all the slopes are negative.
Table 1 presents the remarkable result that of eight
additive spatial models cannabis is independently pre-
dictive for all eight defects and indeed tobacco and alco-
hol do not appear in final models. Similarly in Table 3
cannabis is independently predictive for eight of nine de-
fects in additive SARAR spatial models. Alcohol only
features in the model for Downs syndrome and its re-
gression coefficient is negative. These differences are
compared directly in Table 5, where as noted cannabis is
implicated in 46 terms compared to 15 for alcohol and
18 for tobacco. Cannabis is implicated independently in
27 terms compared to five each for tobacco and alcohol.
The overall conclusion then from this detailed com-
parison must be that cannabis is a relatively more
powerful or more potent human teratogen than
alcohol.
Table 6 Robust generalized linear regression models (Continued)
Parameter Estimate (95%C.I.) P-Value
Cigarettes 0.11 (0, 0.21) 0.0684
Cannabis 0.27 (0, 0.53) 0.0705
Cigarettes: Cannabis −0.01 (−0.02, 0) 0.0920
Exomphalos
Cigarettes: Cannabis 0.1 (0.04, 0.16) 0.0118
Cannabis 0.56 (0.14, 0.98) 0.0289
Cigarettes: Alcohol 1.03 (0.21, 1.85) 0.0357
Alcohol −12.72 (−24.65, −0.8) 0.0661
Cigarettes −3.2 (−5.78, − 0.61) 0.0386
Cigarettes: Alcohol: Cannabis −0.04 (− 0.06, − 0.02) 0.0093
Face
Cleft Palate / Lip
Cannabis 0.57 (0.22, 0.92) 0.0092
Cigarettes: Alcohol 0.04 (0, 0.07) 0.0467
Alcohol: Cannabis −0.12 (−0.2, − 0.04) 0.0128
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Causal inference
A classical criticism of correlative studies is that “correl-
ation does not equal causation.” Judea Pearl, one of the
leading causal statisticians in the world, has described
this criticism as arising from what has been historically
the “causalophobic” science of statistics [45, 46]. In rela-
tion to the present study the following points should be
mentioned. Firstly to observe that an exposure and an
outcome are associated not only statistically but also
across space carries more weight than a simple statistical
association. Secondly inverse probability weighting has
been used in mixed effects and robust structural mar-
ginal models with very highly significant results. Inverse
probability weighting is well established in the literature
as transforming an observational study into a pseudo-
randomized population from which casual inferences
can properly be drawn. Thirdly we have used e-Values
to quantify unmeasured confounding as a notorious
source of extraneous confounding not controlled by
the small number of covariates employed in the
present analysis. E-Values provide a quantitative esti-
mate of the degree of association required of any ex-
traneous factor with both the exposure and the
outcome to explain away the observed effect. Whilst
in the literature e-Values above 1.25 have been stated
to be noteworthy [21] our minimum e-Values ranged
up to infinity in mixed effects models, and up to
5.2 × 10− 13 in spatial models. This finding implies
both the causal nature of the relationship, and also
that the inclusion of further parameters in the model
would not obviate the described effects.
Hence our study demonstrates a causal relationship of
drug and particularly cannabis exposure to several con-
genital anomalies. The causal relationship in this case is
greatly strengthened by the existence of similar results
from other places in the world as described [2–4, 11, 19]
and the existence of a plethora of biological and epigen-
etic processes to account for these effects as mentioned
[3, 11–13, 34, 35, 37, 39, 47–50].
It is further noted that the present findings fulfill
all of the qualitative and quantitative Hill criteria for
causality [51].
Our study has several strengths and limitations. Its
strengths include access to whole population data for
Queensland and a significant portion of the NNSW data.
The CA rates and confidence intervals were already pro-
vided by QLD Health. The NDSHS is a nationally repre-
sentative survey conducted every three years and the
authoritative source for most Australian drug use data.
Our analytical strategy combined CA with drug expos-
ure data which is unusual and useful. We have employed
a variety of powerful statistical techniques in this investi-
gation including geospatial analysis, inverse probability
weighting, mixed models and E-Values. Study limitations
relate mainly to the remote location of the NNSW area
close to the Queensland border and the small numbers
of some anomalies reported. Losses due to treatment
within NSW and to stillbirths and prenatal therapeutic
abortion occurring preferentially in CA babies implies
Table 7 Mixed effects model results for selected congenital
anomalies
Parameter Estimate (95%C.I.) P-Value
Cardiovascular
Atrial_Septal_Defect
Cannabis 0.053 (0.011, 0.096) 0.0280
PDA
Cannabis 0.039 (− 0.004, 0.082) 0.0974
Tetralogy_Fallot
Cannabis 0.079 (0.024, 0.133) 0.0135
GIT
Cigarettes: Alcohol: Cannabis 0.022 (0.004, 0.041) 0.0362
Cigarettes 0.759 (0.064, 1.455) 0.0581
Cigarettes: Alcohol −0.219 (−0.424, − 0.013) 0.0637
Cigarettes: Cannabis −0.082 (− 0.145, − 0.019) 0.0285
Small_Intestinal_Stenosis_Atresia
Alcohol: Cannabis 0.02 (0.008, 0.032) 0.0059
GUT_Defects
Cigarettes 0.278 (0.043, 0.513) 0.0405
Cigarettes: Alcohol −0.085 (−0.156, − 0.015) 0.0370
Cigarettes: Alcohol: Cannabis 0.008 (0.002, 0.014) 0.0295
Cigarettes: Cannabis −0.027 (− 0.048, − 0.006) 0.0289
Chromosomal
Chromosomal
Cannabis 0.084 (0.019, 0.149) 0.0253
Cigarettes: Alcohol: Cannabis −0.001 (− 0.002, 0) 0.0701
Downs_Syndrome
Cigarettes 0.208 (0.024, 0.392) 0.0464
Cigarettes: Alcohol: Cannabis 0.001 (0, 0.001) 0.0636
Cigarettes: Alcohol −0.071 (− 0.124, − 0.018) 0.0231
Body Wall
Musculoskeletal
Cannabis 2.686 (0.671, 4.701) 0.0241
Cigarettes: Alcohol: Cannabis 0.038 (0.01, 0.067) 0.0236
Alcohol: Cannabis −0.79 (−1.385, − 0.195) 0.0246
Cigarettes: Cannabis −0.131 (− 0.228, − 0.034) 0.0228
Gastroschisis
Cannabis 0.065 (0.016, 0.115) 0.0207
Exomphalos
Alcohol: Cannabis 0.042 (0.002, 0.082) 0.0596
Cigarettes: Cannabis −0.006 (−0.011, 0) 0.0874
Reece and Hulse BMC Pharmacology and Toxicology           (2020) 21:75 Page 24 of 28
Table 8 E-values for key regression parameters
Parameter Table Estimate (95%C.I.) RR E-Values
Mixed Effects Models
lme(Congenital_Anomaly ~ Tobacco * Binge_Alcohol * Cannabis)
Cardiovascular Anomalies
Atrial_Septal_Defect
Cannabis Table 7 0.053 (0.011, 0.096) 1.15 (1.03, 1.29) 1.57, 1.20
Tetralogy of Fallot
Cannabis Table 7 0.079 (0.024, 0.133) 1.18 (1.05, 1.32) 1.63, 1.29
Gastrointestinal Tract Anomalies
Cigarettes: Alcohol: Cannabis Table 7 0.022 (0.004, 0.041) 1.3E+ 160 (3.5E+ 30, 5.1E+ 289) Infinity, 6.9E+ 30
Small_Intestinal_Stenosis_Atresia
Alcohol: Cannabis Table 7 0.02 (0.008, 0.032) 1.05 (1.02, 1.09) 1.29, 1.16
Genitourinary Tract Anomalies
Cigarettes: Alcohol: Cannabis Table 7 0.008 (0.002, 0.014) Infinity (6.9E+ 169, Infinity) Infinity, Infinity
Chromosomal Anomalies
Cannabis Table 7 0.084 (0.019, 0.149) 1.32 (1.06, 1.64) 1.97, 1.33
Downs_Syndrome
Cigarettes: Alcohol: Cannabis Table 7 0.001 (0, 0.001) 1.002 (1.000, 1.004) 1.048, 1.009
Body Wall Anomalies
Musculoskeletal
Cannabis Table 7 2.686 (0.671, 4.701) Inf (Inf, Inf) Infinity, Infinity
Gastroschisis
Cannabis Table 7 0.065 (0.016, 0.115) 1.16 (1.04, 1.30) 1.59, 1.24
Exomphalos
Alcohol: Cannabis Table 7 0.042 (0.002, 0.082) 1.07 (1.0045, 1.15) 1.36, 1.07
Geospatial Models
spreml(Congenital_Anomaly ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Binge_Alcohol: Cannabis Table 1 −0.58 (−1.12,-0.03) 0.11 (0.13, 0.87) 17.99, 1.54
Tobacco: Binge_Alcohol: Cannabis Table 1 0.03 (0,0.05) 1.11 (1.00, 1.22) 1.45, 1.07
Tobacco: Cannabis Table 1 −0.09 (− 0.18,0) 0.71 (0.51, 0.99) 2.17, 1.12
Tetralogy_Fallot
Cannabis Table 1 0.09 (0.04,0.14) 1.21 (1.08, 1.37) 1.73, 1.39
Ventricular_Septal_Defect
Tobacco: Cannabis Table 1 −0.11 (− 0.21,− 0.01) 0.57 (0.34, 0.95) 2.90, 1.27
Tobacco: Binge_Alcohol: Cannabis Table 1 0.03 (0,0.06) 1.17 (1.01, 1.37) 1.63, 1.11
Patent_Ductus_Arteriosus
Cannabis Table 1 0.24 (0.02,0.47) 2.63 (1.06, 6.51) 4.71, 1.34
Chromosomal_Defects
Tobacco: Binge_Alcohol: Cannabis Table 1 -0.01 (− 0.01,0) 0.97 (0.95, 0.99) 1.21, 1.13
Binge_Alcohol: Cannabis Table 1 0.05 (0.02,0.09) 1.28 (1.09, 1.50) 1.88, 1.42
Tobacco: Cannabis Table 1 0.02 (0,0.03) 1.07 (1.02, 1.12) 1.35, 1.16
Downs Syndrome
Binge_Alcohol: Cannabis Table 1 0.03 (0.01,0.04) 1.06 (1.03, 1.10) 1.33, 1.22
Small Intestinal Stenosis / Atresia
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that the present findings are conservative estimates. The
very high CA rate reported in Queensland has not been
explained despite formal enquiry. The origin of the
NNSW denominator figure is unclear. NSW Mothers
and Babies reports [7] indicate that during 2008–2015
22,084 babies were born in Northern NSW and 30,848
in the central coast region, totalling 52,932 births. These
regions are shown together in our maps. Hence over 11
times the data is available as was used in this analysis if
it can be properly collated between the two jurisdictions
of NSW and Queensland. This would then facilitate geo-
temporospatial statistical modelling. This proper colla-
tion and assembly of data is a top research priority for
future studies. The remote location of NNSW together
with its somewhat trans-jurisdictional status has appar-
ently made such a collation difficult in the past.
Conclusions
In conclusion study data indicate that prenatal cannabis
exposure is a significant and robust covariate of many
congenital anomalies in NNSW particularly affecting the
cardiovascular, chromosomal, body wall and gastrointes-
tinal systems and is highly significant for 10 cannabis-
related defects on geospatial analysis. Close concordance
between these results and previous reports from Hawaii,
Colorado, and Canada and with unpublished USA stud-
ies suggest our findings are reliable and generalizable.
On all studies cannabis teratogenesis seems to be more
concerning than the established teratogens tobacco and
alcohol. Fulfillment of the criteria for causal relation-
ships has been demonstrated. Further geospatial epi-
demiological and basic science research is a priority
given cannabis commercialization. Even beyond the ob-
vious jurisdictional health cost-shifting implications
careful and thorough further investigation of the terato-
logical profile of NNSW by coordinated investigations
between NSW and Queensland over time to current
would appear to be a major international research prior-
ity with implications far beyond our shores.
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Final Models.
Additional file 2 Supplementary Fig. 1.: Choropleth maps of
congenital anomaly class rates across QLD and NNSW for Congenital
anopmalies A-C. High rates are shown in yellow and low rates in dark
blue. Maps were drawn using R package “sf” [15]. Supplementary Fig.
2.: Choropleth maps of congenital anomaly class rates across QLD and
NNSW for Congenital anopmalies C-P. High rates are shown in yellow
and low rates in dark blue. Maps were drawn using R package “sf” [15].
Supplementary Fig. 3.: Choropleth maps of congenital anomaly class
rates across QLD and NNSW for Congenital anopmalies R-Z. High rates
are shown in yellow and low rates in dark blue. Maps were drawn using
R package “sf” [15].
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Abbreviations
AAP: American Academy of Pediatrics; ACD: All Chromsomal Defects;
ACT: Anal stenosis, Congenital hydrocephalus and Turner syndrome;
AFE: Attributable Fraction in the Exposed; AFP: Attributable Fraction in the
Population; AHA: American Heart Association; ASD: Atrial Septal Defect; AVTP
CDSGDH: Atrial septal defect, Ventricular septal defect, Tetralogy of Fallot,
Patent ductus arteriosus, Chromosomal defects, Downs syndrome, Small
intestinal atresia, Gastroschisis, Diaphragmatic hernia, Hypospadias;
C.I.: Confidence Interval; CA: Congenital Anomalies; CALF: Congential
Anomaly Linked File in Queensland Health [6]; CDC: Center for Disease
Control; CNRD: Cannabis Non-Related defects; CNS: Central Nervous System;
CRAN: Central “R” Archive Network; CRD: Cannabis Related defects;
CVS: Cardiovascular System; E-Values: Expected Values; IPW: Inverse
Probability Weighting; KKP: Kapoor, Kelejian, and Prucha [17]; NDSH
S: National Drug Strategy Household Survey; NNSW: Northern New South
Wales; NRS: Nepnatal Retrieval System; NSW: New South Wales; PCE: Prenatal
Cannabis Exposure; PDA: Patent Ductus Arteriosus; PR: Prevalence Ratio;
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Regressive Error Terms; SEM: Spatial Error Model; sf: Simple Features;
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Table 8 E-values for key regression parameters (Continued)
Parameter Table Estimate (95%C.I.) RR E-Values
Cannabis Table 1 0.02 (0.01,0.03) 1.06 (1.03, 1.10) 1.31, 1.19
Diaphragmatic_Hernia
Cannabis Table 1 7.26 (3.21,11.31) 2.09E+ 09 (1.34E+ 04, 3.27E+ 14) 4.19E+ 09, 2.69E+ 04
Binge_Alcohol: Cannabis Table 1 −2.07 (− 3.25,-0.88) 2.21E-03 (6.67E-05, 0.74) 9.00E+ 02, 26.56
Tobacco: Cannabis Table 1 −0.22 (− 0.38,-0.07) 0.52 (0.33, 0.81) 3.28, 1.77
Tobacco: Binge_Alcohol: Cannabis Table 1 0.06 (0.02,0.11) 1.20 (1.05, 1.36) 1.69, 1.30
Gastroschisis
Cannabis Table 1 0.07 (0.02,0.11) 1.17 (1.06, 1.31) 1.63, 1.30
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